SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 2,400 Shares

Key Points

• Philippe Menu sold 2,400 SOPH shares on April 7 at an average $4.87 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 281,452 shares (a 0.85% reduction).
• Multiple executives (including the CEO, president, CFO and CTO) executed similar pre-arranged sales April 6–7 totaling roughly ~25,000 shares for about $120K, with filings characterizing the trades as routine plan-driven sales.
• SOPH trades near $4.86 with a market cap of ~$333M, recently missed quarterly EPS estimates (reported -$0.28 vs. -$0.20 expected), and carries a mixed analyst profile with a consensus target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Philippe Menu sold 2,400 shares of the firm's stock in a transaction that occurred on Tuesday, April 7th. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00. Following the sale, the insider directly owned 281,452 shares of the company's stock, valued at approximately $1,370,671.24. The trade was a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Philippe Menu also recently made the following trade(s):

• On Monday, April 6th, Philippe Menu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $13,095.00.
• On Thursday, March 19th, Philippe Menu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.79, for a total value of $2,912.32.

SOPHiA GENETICS Price Performance

SOPH stock traded down $0.04 during midday trading on Wednesday, reaching $4.86. 71,758 shares of the company's stock traded hands, compared to its average volume of 188,492. The company has a 50-day simple moving average of $4.78 and a two-hundred day simple moving average of $4.68. SOPHiA GENETICS SA has a 1-year low of $2.58 and a 1-year high of $5.70. The company has a market cap of $332.86 million, a price-to-earnings ratio of -9.53 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The business had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current year.

Key Headlines Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Neutral Sentiment: Multiple insiders executed pre-arranged Rule 10b5-1 sales to cover tax obligations — CEO Jurgi Camblong, President Ross Muken, CFO George Cardoza, CTO Abhimanyu Verma, and others. Collectively ~25,000 shares were sold over April 6–7 for roughly $120k at an average price near $4.85–$4.88. Executives still retain large positions, and filings note these were routine plan-driven sales rather than opportunistic exits. CEO Form 4 President Form 4 Insider Form 4

Institutional Investors Weigh In On SOPHiA GENETICS

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Green Alpha Advisors LLC raised its position in shares of SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company's stock worth $213,000 after acquiring an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock valued at $148,000 after acquiring an additional 6,205 shares during the last quarter. Savvy Advisors Inc. acquired a new stake in SOPHiA GENETICS in the third quarter worth about $48,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the 3rd quarter worth about $49,000. Finally, Perkins Capital Management Inc. bought a new stake in SOPHiA GENETICS during the 4th quarter worth about $49,000. 31.59% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SOPH has been the topic of a number of research analyst reports. BTIG Research reissued a "buy" rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a report on Tuesday, March 3rd. Guggenheim boosted their target price on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SOPHiA GENETICS has an average rating of "Hold" and a consensus target price of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.